Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510

Synendos Therapeutics United States of America United Kingdom

Synendos Therapeutics transitions to a clinical-stage biotech company developing innovative Endocannabinoid System (ECS) treatments for neuropsychiatric, neuroinflammatory and other Central Nervous System (CNS) disordersClinical Trial will investigate the safety, tolerability and pharmacokinetics of Synendos' first-in-class ECS modulatorView original content:https://www.prnewswire.co.uk/news-releases/synendos-therapeutics-ag-granted-ema-clinical-trial-authorisation-for-first-in-class-endocannabinoid-system-modulator-syt-510-302037359.html